SCHEMBL16729404

SCHEMBL16729404

Nc1cc(OC2CCC2)cc(F)c1F

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 1/20 0.38
PTGS2 P35354 1/20 0.38
PARP10 Q53GL7 2/20 0.38
FFAR4 Q5NUL3 5/20 0.36
GRIN2D O15399 1/20 0.36
GRIN3B O60391 1/20 0.36
GRIN1 Q05586 1/20 0.36
GRIN2A Q12879 1/20 0.36
GRIN2B Q13224 1/20 0.36
GRIN2C Q14957 1/20 0.36
GRIN3A Q8TCU5 1/20 0.36
FURIN P09958 2/20 0.33
BACE1 P56817 1/20 0.32
BACE2 Q9Y5Z0 1/20 0.32
PDK2 Q15119 1/20 0.32
PDGFRB P09619 1/20 0.31
PDGFRA P16234 1/20 0.31
GRM5 P41594 1/20 0.31
ALOX5AP P20292 1/20 0.31
FEN1 P39748 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL16716939 0.98 GRIN2D (0.38) PTGS1PTGS2PARP10FFAR4GRIN2D
SCHEMBL26665376 0.87 PTGS1 (0.43) PTGS1PTGS2PARP10FFAR4GRIN2D
SCHEMBL19641855 0.79 PTGS1 (0.38) PTGS1PTGS2PARP10FFAR4GRIN2D
SCHEMBL17012842 0.79 PTGS1 (0.41) PTGS1PTGS2PARP10FFAR4GRIN2D
SCHEMBL30609167 0.79 PTGS1 (0.38) PTGS1PTGS2PARP10FFAR4GRIN2D
SCHEMBL9068406 0.75 PTGS1 (0.48) PTGS1PTGS2PARP10FFAR4GRIN2D
SCHEMBL22289350 0.75 PTGS1 (0.51) PTGS1PTGS2PARP10FFAR4GRIN2D
SCHEMBL18519062 0.75 PTGS1 (0.36) PTGS1PTGS2PARP10FFAR4GRIN2D
SCHEMBL16717600 0.73 PTGS1 (0.47) PTGS1PTGS2PARP10FFAR4GRM5
SCHEMBL9913868 0.72 FFAR4 (0.44) PTGS1PTGS2PARP10FFAR4GRIN2D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230061891-A1 TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS FORMA THERAPEUTICS, INC. 2023-03-02 US disclosed
US-11111229-B2 Tetrahydroquinoline compositions as BET bromodomain inhibitors FORMA THERAPEUTICS, INC. (US) 2021-09-07 US disclosed
EP-3799872-A1 TETRAHYDROQUINOLINE DERIVATIVES FOR USE AS BET INHIBITORS Forma Therapeutics, Inc. (US) 2021-04-07 EP disclosed
EP-3071203-B1 TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS FORMA THERAPEUTICS INC (US) 2020-12-23 EP disclosed
US-20200369642-A1 TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS FORMA THERAPEUTICS, INC. 2020-11-26 US disclosed
US-10336722-B2 Tetrahydroquinoline compositions as BET bromodomain inhibitors FORMA THERAPEUTICS, INC. (US) 2019-07-02 US disclosed
US-20190127347-A1 TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS FORMA THERAPEUTICS, INC. 2019-05-02 US disclosed
US-20180215766-A1 TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS FORMA THERAPEUTICS, INC. 2018-08-02 US disclosed
US-20180215766-A1 TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS FORMA THERAPEUTICS, INC. 2018-08-02 US disclosed
US-20160257692-A1 TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS FORMA THERAPEUTICS, INC. 2016-09-08 US disclosed
US-20160256448-A1 TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS FORMA THERAPEUTICS, INC. 2016-09-08 US disclosed
US-20160257692-A1 TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS FORMA THERAPEUTICS, INC. 2016-09-08 US disclosed
US-20160256448-A1 TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS FORMA THERAPEUTICS, INC. 2016-09-08 US disclosed
US-9388161-B2 Tetrahydroquinoline compositions as BET bromodomain inhibitors FORMA THERAPEUTICS, INC. (US) 2016-07-12 US disclosed
US-9388161-B2 Tetrahydroquinoline compositions as BET bromodomain inhibitors FORMA THERAPEUTICS, INC. (US) 2016-07-12 US disclosed
US-20150232445-A1 TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS FORMA THERAPEUTICS, INC. 2015-08-20 US disclosed
US-20150232445-A1 TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS FORMA THERAPEUTICS, INC. 2015-08-20 US disclosed
WO-2015074064-A2 TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS BAIR KENNETH W (US) 2015-05-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160256448-A1 TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS BRD4, BRD3, BRD1 PTGS1 2660/4885PTGS2 3355/4885PARP10 75/4885
US-20180215766-A1 TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS BRD4, BRD3, BRD1 PTGS1 2660/4885PTGS2 3355/4885PARP10 75/4885
US-20190127347-A1 TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS BRD4, BRD3, BRD1 PTGS1 2660/4885PTGS2 3355/4885PARP10 75/4885
US-10336722-B2 Tetrahydroquinoline compositions as BET bromodomain inhibitors BRD4, BRD3, BRD1 PTGS1 2660/4885PTGS2 3355/4885PARP10 75/4885
US-11111229-B2 Tetrahydroquinoline compositions as BET bromodomain inhibitors BRD4, BRD3, BRD1 PTGS1 2660/4885PTGS2 3355/4885PARP10 75/4885
US-20200369642-A1 TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS BRD4, BRD3, BRD1 PTGS1 2660/4885PTGS2 3355/4885PARP10 75/4885
US-20150232445-A1 TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS BRD4, BRD3, BRD1 PTGS1 2660/4885PTGS2 3355/4885PARP10 75/4885
US-20230061891-A1 TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS BRD4, BRD3, BRD1 PTGS1 2660/4885PTGS2 3355/4885PARP10 75/4885
US-20160257692-A1 TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS BRD4, BRD3, BRD1 PTGS1 2660/4885PTGS2 3355/4885PARP10 75/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.